Cargando…

Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. Obesity is the most common and well-established risk factor for NAFLD, but there are large interindividual differences in the relationship between weight status and the development of NAFLD. Beta-3-adrenerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Yuki, Oniki, Kentaro, Kumagae, Naoki, Morita, Kazunori, Otake, Koji, Ogata, Yasuhiro, Saruwatari, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942826/
https://www.ncbi.nlm.nih.gov/pubmed/31929840
http://dx.doi.org/10.1155/2019/4065327
_version_ 1783484778472800256
author Sakamoto, Yuki
Oniki, Kentaro
Kumagae, Naoki
Morita, Kazunori
Otake, Koji
Ogata, Yasuhiro
Saruwatari, Junji
author_facet Sakamoto, Yuki
Oniki, Kentaro
Kumagae, Naoki
Morita, Kazunori
Otake, Koji
Ogata, Yasuhiro
Saruwatari, Junji
author_sort Sakamoto, Yuki
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. Obesity is the most common and well-established risk factor for NAFLD, but there are large interindividual differences in the relationship between weight status and the development of NAFLD. Beta-3-adrenergic receptor (ADRB3) plays a key role in the development of visceral obesity and insulin resistance; however, the effect of ADRB3 polymorphisms on the risk of NAFLD remains unclear. We investigated whether or not a common rs4994 polymorphism (T190C) in the ADRB3 gene is associated with the risk of NAFLD through an increase in the body mass index (BMI) among the general population. We performed cross-sectional and longitudinal analyses in a total of 591 Japanese health screening program participants. Among the overweight or obese subjects, but not normal-weight subjects, individuals with the C/C genotype had a higher risk of developing NAFLD in comparison to those with other genotypes in the cross-sectional analysis (odds ratio: 4.40, 95% confidence interval (CI): 1.08–17.93). Meanwhile, the receiver operating characteristic curve indicated that the association between an increase in the BMI and the presence of NAFLD in subjects with the C/C genotype (area under the curve: 0.91, 95% CI: 0.78–1.00) was more pronounced in comparison to subjects with other genotypes. These above-described findings were verified by the analyses using a replicated data set consisting of 5,000 random samples from original data sets. Furthermore, among the 291 subjects for whom longitudinal medical information could be collected and who did not have NAFLD at baseline, the Cox proportional hazard model also confirmed that overweight or obese status and the C/C genotype were concertedly related to the increased risk of NAFLD development. These results suggest that genotyping the ADRB3 rs4994 polymorphism may provide useful information supporting the development of personalized BMI-based preventive measures against NAFLD.
format Online
Article
Text
id pubmed-6942826
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-69428262020-01-12 Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals Sakamoto, Yuki Oniki, Kentaro Kumagae, Naoki Morita, Kazunori Otake, Koji Ogata, Yasuhiro Saruwatari, Junji Dis Markers Research Article Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases. Obesity is the most common and well-established risk factor for NAFLD, but there are large interindividual differences in the relationship between weight status and the development of NAFLD. Beta-3-adrenergic receptor (ADRB3) plays a key role in the development of visceral obesity and insulin resistance; however, the effect of ADRB3 polymorphisms on the risk of NAFLD remains unclear. We investigated whether or not a common rs4994 polymorphism (T190C) in the ADRB3 gene is associated with the risk of NAFLD through an increase in the body mass index (BMI) among the general population. We performed cross-sectional and longitudinal analyses in a total of 591 Japanese health screening program participants. Among the overweight or obese subjects, but not normal-weight subjects, individuals with the C/C genotype had a higher risk of developing NAFLD in comparison to those with other genotypes in the cross-sectional analysis (odds ratio: 4.40, 95% confidence interval (CI): 1.08–17.93). Meanwhile, the receiver operating characteristic curve indicated that the association between an increase in the BMI and the presence of NAFLD in subjects with the C/C genotype (area under the curve: 0.91, 95% CI: 0.78–1.00) was more pronounced in comparison to subjects with other genotypes. These above-described findings were verified by the analyses using a replicated data set consisting of 5,000 random samples from original data sets. Furthermore, among the 291 subjects for whom longitudinal medical information could be collected and who did not have NAFLD at baseline, the Cox proportional hazard model also confirmed that overweight or obese status and the C/C genotype were concertedly related to the increased risk of NAFLD development. These results suggest that genotyping the ADRB3 rs4994 polymorphism may provide useful information supporting the development of personalized BMI-based preventive measures against NAFLD. Hindawi 2019-12-17 /pmc/articles/PMC6942826/ /pubmed/31929840 http://dx.doi.org/10.1155/2019/4065327 Text en Copyright © 2019 Yuki Sakamoto et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakamoto, Yuki
Oniki, Kentaro
Kumagae, Naoki
Morita, Kazunori
Otake, Koji
Ogata, Yasuhiro
Saruwatari, Junji
Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title_full Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title_fullStr Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title_full_unstemmed Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title_short Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals
title_sort beta-3-adrenergic receptor rs4994 polymorphism is a potential biomarker for the development of nonalcoholic fatty liver disease in overweight/obese individuals
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942826/
https://www.ncbi.nlm.nih.gov/pubmed/31929840
http://dx.doi.org/10.1155/2019/4065327
work_keys_str_mv AT sakamotoyuki beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT onikikentaro beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT kumagaenaoki beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT moritakazunori beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT otakekoji beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT ogatayasuhiro beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals
AT saruwatarijunji beta3adrenergicreceptorrs4994polymorphismisapotentialbiomarkerforthedevelopmentofnonalcoholicfattyliverdiseaseinoverweightobeseindividuals